Vidofludimus - 4SC-101 | SC 12267

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 2377

CAS [717824-30-1]

MF C20H18FNO4
MW 355.36

  • Purity: 99%
  • Soluble in DMSO

Vidofludimus

Description

Oral immunomodulatory drug that inhibits dihydroorotate dehydrogenase (DHODH; IC50 value 134 nM for human DHODH mediated DCIP reduction) and lymphocyte proliferation in vitro. Vidofludimus inhibits the proliferation of human peripheral blood mononuclear cells (PBMCs) stimulated with Phytohemagglutinin-L, and interleukin (IL)-17 secretion from human peripheral blood mononuclear cells in a dose-related fashion (IC50 of 6 µM approx.) and independently of lymphocyte proliferation. May be applied for treatment of rheumatoid arthritis and inflammatory bowel disease, and as immunosuppressant after renal transplantation.
Order
Size Unit Price Stock
5 mg €125.00 In Stock
25 mg €425.00 In Stock
Special Offers
Size Unit Price Stock
2 x 25 mg €620.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...